Polycystic Kidney Disease Drugs Market by Type, Treatment, Diagnosis, Distribution Channels, End-User - Global Forecast 2025-2030- Product Image

Sale

Polycystic Kidney Disease Drugs Market by Type, Treatment, Diagnosis, Distribution Channels, End-User - Global Forecast 2025-2030

Report
198 Pages
October 2024
Region: Global
360iResearch™
ID: 5674533

UP TO €681EUR$697USD£568GBP OFF until Dec 31^st 2024

The Polycystic Kidney Disease Drugs Market grew from USD 519.56 million in 2023 to USD 556.57 million in 2024. It is expected to continue growing at a CAGR of 5.95%, reaching USD 778.82 million by 2030.

Polycystic Kidney Disease (PKD) drugs scope involves medications used in the treatment and management of PKD, a genetic disorder characterized by the growth of numerous cysts in the kidneys, leading to renal failure. The market necessity arises from the growing prevalence of PKD and the lack of curative treatments, necessitating the development of drugs that can slow disease progression, manage symptoms, or provide palliative care. Applications primarily involve tolvaptan, an FDA-approved drug that has been a significant breakthrough in managing Autosomal Dominant Polycystic Kidney Disease (ADPKD), and the pipeline for novel therapies such as gene therapy and targeted treatments. End-use scope is predominantly centered around hospitals, specialty clinics, and homecare settings where these drugs are administered.

Market insights reveal a growing demand influenced by increasing awareness, supportive government initiatives, and advancements in diagnostic practices. Key growth factors include the rise in incidence rates, enhanced healthcare access, and ongoing research efforts. Opportunities lie in the development of novel therapies and expanding the use of existing drugs for broader indications, alongside increasing collaborations between pharmaceutical companies and research institutions. To leverage these opportunities, firms should invest in R&D focused on innovative treatments like gene editing and personalized medicine approaches. However, the market faces challenges including high cost of drug development, stringent regulatory requirements, and side effects associated with current treatments, which can slow adoption rates.

Best areas for innovation include enhancing existing drug formulations, exploring gene therapy options, and improving patient adherence through digital health technologies. The market is characterized by high competition, quick technological adoption, and a focus on strategic alliances to enhance portfolio offerings. Understanding patient needs and focusing on breakthrough therapies in genetic modification and biologics could present lucrative opportunities for business growth. Addressing the challenges of affordability and accessibility while ensuring compliance with regulatory standards remains crucial for sustained market expansion.

Understanding Market Dynamics in the Polycystic Kidney Disease Drugs Market

The Polycystic Kidney Disease Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Prevalence of chronic kidney disorders among population
- Rising collaboration and research on polycystic kidney disease
- Growing healthcare expenditure in economies
Market Restraints
- Complexities associated with the production
Market Opportunities
- Development of advanced medications by market players
- Strategic alliances and investment for capacity expansion
Market Challenges
- Issues pertaining to quality management

Exploring Porter’s Five Forces for the Polycystic Kidney Disease Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Polycystic Kidney Disease Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Polycystic Kidney Disease Drugs Market

External macro-environmental factors deeply influence the performance of the Polycystic Kidney Disease Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Polycystic Kidney Disease Drugs Market

The Polycystic Kidney Disease Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Polycystic Kidney Disease Drugs Market

The Polycystic Kidney Disease Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Polycystic Kidney Disease Drugs Market

The Polycystic Kidney Disease Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Polycystic Kidney Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Apotex Inc., AstraZeneca PLC, Centessa Pharmaceuticals Limited, Dr. Reddys Laboratories Ltd., Galapagos NV, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Polycystic Kidney Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- ADPKD
- ARPKD
Treatment
- Medication
- Surgery
Diagnosis
- CT Scan
- MRI
- Ultra Sound
Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
End-User
- Hospital & Clinics
- Speciality Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Polycystic Kidney Disease Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic kidney disorders among population
5.1.1.2. Rising collaboration and research on polycystic kidney disease
5.1.1.3. Growing healthcare expenditure in economies
5.1.2. Restraints
5.1.2.1. Complexities associated with the production
5.1.3. Opportunities
5.1.3.1. Development of advanced medications by market players
5.1.3.2. Strategic alliances and investment for capacity expansion
5.1.4. Challenges
5.1.4.1. Issues pertaining to quality management
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Polycystic Kidney Disease Drugs Market, by Type

6.1. Introduction
6.2. ADPKD
6.3. ARPKD

7. Polycystic Kidney Disease Drugs Market, by Treatment

7.1. Introduction
7.2. Medication
7.3. Surgery

8. Polycystic Kidney Disease Drugs Market, by Diagnosis

8.1. Introduction
8.2. CT Scan
8.3. MRI
8.4. Ultra Sound

9. Polycystic Kidney Disease Drugs Market, by Distribution Channels

9.1. Introduction
9.2. Hospital Pharmacy
9.3. Retail Pharmacy

10. Polycystic Kidney Disease Drugs Market, by End-User

10.1. Introduction
10.2. Hospital & Clinics
10.3. Speciality Clinics

11. Americas Polycystic Kidney Disease Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Polycystic Kidney Disease Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Polycystic Kidney Disease Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. Apotex Inc.
15.1.3. AstraZeneca PLC
15.1.4. Centessa Pharmaceuticals Limited
15.1.5. Dr. Reddys Laboratories Ltd.
15.1.6. Galapagos NV
15.1.7. Johnson & Johnson Services, Inc.
15.1.8. Merck & Co., Inc.
15.1.9. Novartis AG
15.1.10. Otsuka Pharmaceutical Co., Ltd.
15.1.11. Reata Pharmaceuticals Inc.
15.1.12. Sanofi S.A.
15.1.13. Teva Pharmaceutical Industries Ltd.
15.1.14. XORTX Therapeutics Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET DYNAMICS
FIGURE 7. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
FIGURE 12. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
FIGURE 14. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ADPKD, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ARPKD, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 9. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 12. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ULTRA SOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 16. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 19. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 40. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 41. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 45. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 46. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 67. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 68. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 72. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 73. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 82. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 83. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 92. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 97. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 112. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 113. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 128. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 129. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 133. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 134. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 138. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 139. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 148. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 149. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 158. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 159. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 173. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 174. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 176. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 178. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 179. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 182. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 183. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 184. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 201. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 202. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 204. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 212. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 213. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 217. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 218. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 219. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 231. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 232. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET LICENSE & PRICING

Companies Mentioned

The leading players in the Polycystic Kidney Disease Drugs Market, which are profiled in this report, include:

AbbVie Inc.
Apotex Inc.
AstraZeneca PLC
Centessa Pharmaceuticals Limited
Dr. Reddys Laboratories Ltd.
Galapagos NV
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Reata Pharmaceuticals Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
XORTX Therapeutics Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	198
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 556.57 Million
Forecasted Market Value ( USD ) by 2030	$ 778.82 Million
Compound Annual Growth Rate	5.9%
Regions Covered	Global
No. of Companies Mentioned	14

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3464EUR$3,545USD£2,892GBP €3849EUR$3,939USD£3,213GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6128EUR$6,272USD£5,116GBP €6809EUR$6,969USD£5,684GBP

Understanding Market Dynamics in the Polycystic Kidney Disease Drugs Market

Exploring Porter’s Five Forces for the Polycystic Kidney Disease Drugs Market

Applying PESTLE Analysis to the Polycystic Kidney Disease Drugs Market

Analyzing Market Share in the Polycystic Kidney Disease Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Polycystic Kidney Disease Drugs Market

Strategic Recommendations for Success in the Polycystic Kidney Disease Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Polycystic Kidney Disease Market

Polycystic Kidney Disease Drugs Market 2024-2028

Polycystic Kidney Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

Late-stage chronic kidney disease (CKD) - Market Insight, Epidemiology and Market Forecast - 2034

Moderate and Severe Chronic Kidney Disease (CKD) - Market Insight, Epidemiology and Market Forecast - 2034

About the Polycystic Kidney Disease Drug Market